The concomitant use of buprenorphine and CYP3A4 inducers can reduce the plasma focus of buprenorphine [see CLINICAL PHARMACOLOGY], most likely causing diminished efficacy or onset of the withdrawal syndrome in people who have made Actual physical dependence to buprenorphine.For anyone who is prescribed a dose of 2 or more SUBUTEX sublingual tablets